Benzinga | May 11, 2021 10:12AM EDT

Canaccord Genuity Initiates Coverage On Akoya Biosciences with Buy Rating, Announces Price Target of $25

Canaccord Genuity analyst Max Masucci initiates coverage on Akoya Biosciences (NASDAQ:AKYA) with a Buy rating and announces Price Target of $25.